Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
J Mooney, SR Reddy, E Chang, MS Broder… - Journal of Managed …, 2021 - jmcp.org
… Despite the acceptance of antifibrotic drug therapy into IPF … on the effect of antifibrotic therapy
on IPF outcomes outside of … of all-cause mortality and acute hospitalizations in antifibrotic-…
on IPF outcomes outside of … of all-cause mortality and acute hospitalizations in antifibrotic-…
Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy
Y Suzuki, Y Aono, M Kono, H Hasegawa… - …, 2021 - Wiley Online Library
… Besides its efficacy on the annual rate of decline in FVC, emerging evidence has confirmed
that antifibrotic therapy (AFT) reduces the risks of acute exacerbation (AE), 16 respiratory-…
that antifibrotic therapy (AFT) reduces the risks of acute exacerbation (AE), 16 respiratory-…
Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis
… Our findings demonstrate that antifibrotic treatment decreases the risk of all-cause mortality
and AE in patients with IPF. An expected limitation is study heterogeneity with pooled analysis…
and AE in patients with IPF. An expected limitation is study heterogeneity with pooled analysis…
Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis
TM Dempsey, LR Sangaralingham, X Yao… - American journal of …, 2019 - atsjournals.org
… fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and …
mode of steroid therapy between the untreated and antifibrotic therapy groups could explain …
mode of steroid therapy between the untreated and antifibrotic therapy groups could explain …
When to start and when to stop antifibrotic therapies
SE Torrisi, M Pavone, A Vancheri… - European Respiratory …, 2017 - Eur Respiratory Soc
… with mortality should be by themselves very good common-sense reasons to start antifibrotic
therapies as … lower risk for all mortality outcomes (all-cause mortality, treatment-emergent all-…
therapies as … lower risk for all mortality outcomes (all-cause mortality, treatment-emergent all-…
[HTML][HTML] Strategies for anti-fibrotic therapies
J Rosenbloom, FA Mendoza, SA Jimenez - Biochimica et Biophysica Acta …, 2013 - Elsevier
… to convert this new knowledge into novel and effective anti-fibrotic drugs will be forthcoming
in the near … Novel pathogenesis-based strategies will result in effective anti-fibrotic therapies. …
in the near … Novel pathogenesis-based strategies will result in effective anti-fibrotic therapies. …
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
TM Maher, ME Strek - Respiratory research, 2019 - Springer
… and mortality. Individual clinical trials have not been powered to show reductions in mortality…
as observational studies, suggest that antifibrotic therapies improve life expectancy. Despite …
as observational studies, suggest that antifibrotic therapies improve life expectancy. Despite …
Advances in antifibrotic therapy
Z Ghiassi-Nejad, SL Friedman - Expert review of gastroenterology …, 2008 - Taylor & Francis
Sustained progress in defining the molecular pathophysiology of hepatic fibrosis has led to
a comprehensive framework for developing antifibrotic therapies. Indeed, the single greatest …
a comprehensive framework for developing antifibrotic therapies. Indeed, the single greatest …
[HTML][HTML] Effect of antifibrotic therapy on survival in patients with idiopathic pulmonary fibrosis
JA de Andrade, ML Neely, AS Hellkamp, DA Culver… - Clinical Therapeutics, 2023 - Elsevier
… the effect of antifibrotic therapy on mortality and other … in mortality can be attributed to the
use of antifibrotic therapy. Our … of mortality in patients with IPF treated with antifibrotic therapy. A …
use of antifibrotic therapy. Our … of mortality in patients with IPF treated with antifibrotic therapy. A …
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
BF Collins, G Raghu - European Respiratory Review, 2019 - Eur Respiratory Soc
… controlled trials using mortality as the primary end-point require a large number of patients
and long-term follow-up. This is based on a relatively low all-cause mortality rate among …
and long-term follow-up. This is based on a relatively low all-cause mortality rate among …
相关搜索
- idiopathic pulmonary fibrosis antifibrotic therapy
- antifibrotic therapies mortality and hospitalization
- cause of mortality sarcopenia in patients
- fibrotic lung disease antifibrotic therapy
- survival in patients antifibrotic therapy
- acute exacerbation antifibrotic therapy
- meta analysis antifibrotic therapy
- systematic review antifibrotic therapy